Kornimate/medical-research-clean huggingface dataset:
aldh1a1 expression in invasive mammary carcinoma

Conditions: Breast Cancer

Summary: aldh1a1 isozyme oxidizes retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. much emphasis has been focused on aldh1a1 as a csc marker. high expression of aldh1a1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. cscs markers are one of the emerging prognostic biomarkers. aldh1a1 isozyme oxidizes retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. much emphasis has been focused on aldh1a1 as a csc marker. high expression of aldh1a1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Eligibility criteria:
inclusion criteria: * patients with invasive mammary carcinoma carcinoma and underwent surgery exclusion criteria: * cases received pre-operative chemotherapy or radiotherapy. * cases with insufficient clinical data.

Keywords: breast cancer cscs aldh1a1
comparison of aliskiren and amlodipine on insulin resistance and endothelial dysfunction in patients with hypertension and metabolic syndrome

Conditions: High Blood Pressure; Metabolic Syndrome; Insulin Resistance; Endothelial Dysfunction

Summary: the purpose of this study was to determine the effects of aliskiren on insulin resistance (ir) and endothelial dysfunction (ed) in patients with high blood pressure and metabolic syndrome. the efficacy of aliskiren was compared to amlodipine.


Eligibility criteria:
inclusion criteria: * male or female adults aged 18 to 55 years, inclusive. * sitting diastolic blood pressure ≥80 mm hg and/or sitting systolic blood pressure ≥ 130 at screening. * metabolic syndrome as defined by the adult treatment panel (atp) iii criteria. * hypertension (defined above) and impaired glucose tolerance (igt) or impaired fasting glucose (ifg) plus one or more out of the remaining 3 criteria to satisfy entry into the study. igt and ifg will be classified according to american diabetes association (ada) guidelines: * ifg: fasting plasma glucose of 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) * igt: two-hour plasma glucose of 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) * abnormal positron emission tomography (pet) results at baseline. (myocardial blood flow (mbf) of less than or equal to 35%.) * abnormal euglycemic clamp results at baseline. (glucose infusion rate (ginf) of less than or equal to 4.2 mg/kg/min.) * body mass index (bmi) of less than 40. exclusion criteria: * smokers (use of tobacco products in the recent past) * cardiovascular abnormalities including myocardial infarction, angina pectoris, hypertensive encephalopathy, stroke, transient ischemic attack, valvular heart disease, ventricular arrhythmia, a-v block, atrial fibrillation or cardiac revascularization/angioplasty in the past 12 months. * symptoms or clinical evidence of congestive heart failure or known left ventricular ejection fraction \< 40%. * supine blood pressure ≥ 160 mmhg systolic or ≥110 mmhg diastolic. * clinically significant echocardiogram (ecg) abnormalities, including history of a prolonged qt-interval syndrome. * significant autonomic dysfunction. * severe bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). * clinically significant drug allergy, atopic allergy (asthma, urticaria, eczematous dermatitis). * pregnant or breastfeeding females. pre-menopausal females who are not practicing a non-hormonal method of birth control. * african americans will not be eligible for this study. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: high blood pressure hypertension metabolic syndrome insulin resistance endothelial dysfunction pre-diabetic amlodipine, aliskiren, igt, ifg, mbf
alzheimer's disease genetics study

Conditions: Alzheimer Disease; Late Onset Alzheimer Disease; Dementia

Summary: the purpose of the alzheimer's disease genetics study is to identify the genes that are responsible for causing alzheimer's disease (ad). one of the ways in which the risk factor genes for late onset ad can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with ad or dementia.

the purpose of the alzheimer's disease genetics study is to help identify the genes that may be responsible for causing alzheimer's disease (ad) by collecting genetic material from families with multiple members diagnosed with ad. qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of ad or dementia. local study sites are located all over the united states, and arrangements may be made for eligible families who do not live near a participating site. the biological samples and data from these families will be made available to qualified researchers, who must sign a materials transfer agreement (mta) in order to protect the privacy rights of study participants before receiving samples and data.

Eligibility criteria:
inclusion criteria: * two living family members diagnosed with ad or other dementia with any age of onset * biological samples available * fresh blood, or * immortalized lymphoblastic cell lines, or * 3-5 grams of frozen cerebral cortex; fixed samples are not accepted please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members. exclusion criteria: * does not meet inclusion criteria * member of a family that was included in the national institute of mental health ad genetics sib pair collection

Keywords: alzheimer disease late onset alzheimer disease risk factor genes genetics initiative dementia
a polysomnographic study of single-dose gabapentin in transient insomnia induced by a sleep phase advance

Conditions: Transient Insomnia

Summary: the purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep in subjects with transient insomnia.


Eligibility criteria:
inclusion criteria: * aged \>/= 18 years * females of child-bearing potential using medically-acceptable method of birth control \>/= 1 month prior to screening exclusion criteria: * current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition) * recreational drug use within past 30 days
efficacy and safety of mp-424, interferon beta (ifn beta), and ribavirin(rbv) in treatment-naïve or having received interferon based therapy with chronic hepatitis c (chc)

Conditions: Chronic Hepatitis C(CHC)

Summary: this study will evaluate the efficacy and safety of mp-424 with ifn beta and rbv in patients with genotype 1/2 hepatitis c, who are treatment-naïve or have received its treatment before.


Eligibility criteria:
inclusion criteria: * genotype 1 or 2, chronic hepatitis c, with depression(including the past) * treatment-naïve(genotype 1 only) or patient who have ever had previous ifn based treatment * able and willing to follow contraception requirements exclusion criteria: * cirrhosis of the liver or hepatic failure * hepatitis b surface antigen-positive or hiv antibodies-positive * history of, or concurrent hepatocellular carcinoma * history of, or concurrent serious depression, schizophrenia, or suicide attempt in the past * pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Keywords: feron
vaccination perception in inflammatory conditions - flu, pneumonia and covid-19

Conditions: Inflammatory Disease; Rheumatoid Arthritis; Psoriatic Arthritis; Systemic Lupus Erythematosus; Ankylosing Spondylitis; Vasculitis; Reactive Arthritis; Inflammatory Bowel Diseases

Summary: people with inflammatory diseases are often treated with medications that act to suppress the immune-system, increasing the risk of catching infections. consequently, vaccination with the pneumonia and seasonal flu vaccines is recommended for them. they were also prioritised to receive the covid-19 vaccines early in the national rollout. however, the uptake of the pneumonia and seasonal flu vaccines among this group is lower than ideal. there may be many reasons why they do or do not seek to be vaccinated for these infections, such as the belief it may cause their disease to flare up or lack of knowledge of vaccines effectiveness. anecdotally there was a high uptake of covid-19 vaccines in adults with inflammatory conditions, however, concerns about vaccine-induced disease flare-ups and reports of complications deterred some from being vaccinated. a better understanding of why people do and do not seek vaccination may result in more targeted messaging for patients to help overcome vaccine hesitancy for these infectious diseases. this study aims to explore the drivers and barriers to being vaccinated among adults with common inflammatory conditions and on immune-suppressing medication. they will be invited to participate in a single, semi-structured interview. interviews will be face-to-face, by telephone or video-call, last up to one hour, and digitally audio-recorded. they will explore participants' understanding of pneumonia, seasonal flu and covid-19 and the risk they pose to their health, their understanding of vaccinations, beliefs of the benefits and risks of vaccinations for these infections, and reasons for seeking or not seeking vaccination. findings will inform messaging about being vaccinated for these infections in patient education leaflets, such as those by patient charities regularly provided at speciality clinics. they will also be disseminated to healthcare professionals to help them better understand the drivers and barriers to vaccination.


Eligibility criteria:
inclusion criteria: * age at-least 18 years, * diagnosed with either rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, vasculitis (small or large vessel), or reactive arthritis, and * at-least one prescription of either methotrexate, azathioprine, 5-mercaptopurine, sulfasalazine, mycophenolate mofetil, leflunomide, ciclosporin, tacrolimus, or sirolimus, biologic agents (such as anti-tnf, anti-cd 20 etc). * ability to give informed consent exclusion criteria: * age \< 18 years * dementia: making it impossible to give informed consent and to comply with interview
clinical study to evaluate the efficacy and safety of octagam 10% in idiopathic thrombocytopenic purpura in adults

Conditions: Immune Thrombocytopenic Purpura

Summary: octagam is a solvent/detergent-treated human normal immunoglobulin (igiv) solution for intravenous administration. octagam 5% is currently registered in about 80 countries. this study evaluated the efficacy and safety of octagam 10% in idiopathic thrombocytopenic purpura (itp) in adults. as octagam 10% is essentially similar to octagam 5%, it is expected that octagam 10% is as efficacious and safe (in respect to viral safety) as octagam 5%.

the primary objective of the study was to investigate the efficacy of octagam® 10% in correcting platelet count. the blood count as well as laboratory chemistry were checked repeatedly up to day 21. the secondary objective of the study was to investigate the safety of octagam® 10%. safety was assessed by monitoring vital signs, evaluating adverse events, assessing laboratory parameters, and by viral safety testing.

Eligibility criteria:
key inclusion criteria: * diagnosis of idiopathic thrombocytopenic purpura (itp) according to standard criteria. * platelet count ≤ 20 x 10\^9/l. key exclusion criteria: * chronic refractory itp patients. * thrombocytopenia secondary to other diseases, or drug related thrombocytopenia. * administration of igiv, anti-d, or other platelet enhancing drugs within 30 days before enrollment. * administration of thrombocyte concentrates within 72 hours before baseline. * experimental treatment (eg, rituximab) within 3 months before enrollment. * prophylactic preoperative treatment for elective splenectomy. * severe liver or kidney disease. * pregnant or nursing female. * history of hypersensitivity to blood or plasma derived products. * emergency operation. * live viral vaccination within the last month prior to study entry. * known iga deficiency and antibodies against iga.
research on risk factors and interventions of polycystic ovary syndrome complicated with depression and anxiety

Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; Depression, Anxiety

Summary: the current study intends to establish a prediction method and evaluation system for polycystic ovary syndrome (pcos) complicated with affective disorder, such as depression and anxiety, through the epidemiological investigation. randomized controlled studies on the efficacy of various intervention methods should be carried out to develop early intervention measures and methods in order to reduce the harm of psychological disorders, to facilitate the mental health of pcos patients, and thus to improve the quality of life.

pcos is one of the most common reproductive endocrine and metabolic diseases in women of adolescence and childbearing age. the prevalence of pcos in reproductive women is as high as 5-10%, about 50-80% of whom are infertile and need ovulation induction or in vitro fertilization-embryo transfer (ivf-et). ovulation/anovulation and hyperandrogenemia are two main features of pcos. moreover, about 50-60% of pcos patients present insulin resistance/hyperinsulinemia. the probability of miscarriage in pcos is also higher than that of control women. pregnancy complications in pcos patients, such as gestational diabetes, preeclampsia, etc., and long-term complications of metabolic syndrome and endometrial cancer are more likely to happen. these not only greatly affect women's reproductive health, but also seriously endanger their psychological status. a large sample of data has shown that the risk of depression in women with pcos is 3.78 times higher than that of the control women, 5.62 times for anxiety, and 1.78 times for bipolar disorder. with the economic development, more and more attention is paid to the quality of life including their mental health. however, there is few data on the risk factors of depression, anxiety and other psychological disorders in women with pcos. there is a lack of effective evaluation and prediction systems. it is urgent to establish a risk assessment system for pcos complicated with psychological diseases through scientific and systematic research, to formulate comprehensive intervention measures to improve the quality of life of women with pcos and to reduce the incidence of affective disorders.

Eligibility criteria:
inclusion criteria: * patients diagnosed as pcos according to rotterdam criteria 2003, aged between 18 and 40 years old, and no willing to get pregnant in a year. at least two of the following three criteria were met: clinical and/or biochemical signs of hyperandrogenism, oligo- and/or anovulation, and polycystic ovary on ultrasonography, exclusion criteria: * any other related diseases, such as adrenal congenital hyperplasia, cushing's syndrome, androgen-secreting tumors, hashimoto's thyroiditis, hyperthyroidism or hypothyroidism

Keywords: polycystic ovary syndrome depression anxiety bipolar disorder intervention
neoadjuvant radiotherapy and immediate implant-based breast reconstruction

Conditions: Breast Cancer; Implant Breast Reconstruction; Neoadjuvant Radiotherapy

Summary: neoadjuvant radiotherapy(nart) followed by mastectomy and immediate diep flap reconstruction is feasible and technically safe. however, reports of nact followed immediate implant-based breast reconstruction are rare. some studies have shown that nart followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. it's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. so, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after nart.

radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results, including severe capsular contracture, mastectomy flap necrosis ,reoperation and so on. postmastectomy radiotherapy( pmrt )is associated with implant reconstruction failure. prada study has shown neoadjuvant radiotherapy followed by skin-sparing mastectomy and immediate diep flap reconstruction is feasible and technically safe. the investigators assume that neoadjuvant radiotherapy can avoid the negative effects of pmrt on an implant and the capsule of an implant and would lead to better cosmetic results and less complications compared to pmrt. furthermore, some studies have shown that nart could potentially result in shorter time between diagnosis and treatment completion. so, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after nart.

Eligibility criteria:
inclusion criteria: women \>18 years with histopathologically-confirmed breast cancer, who: * require mastectomy for any reason * a known indication for (adjuvant) radiotherapy * require implant-based breast reconstruction exclusion criteria: * inability to give informed consent * mdt unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings * previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla * pregnant or lactating * inflammatory breast cancer

Keywords: neoadjuvant radiotherapy, implant, breast reconstruction
doxycycline prophylaxis at vacuum aspiration trial

Conditions: Endometritis

Summary: this study is a randomized, double-blinded, controlled trial comparing two regimens of doxycycline for the prevention of infection after surgical abortion. one thousand women undergoing surgical abortion in the first trimester will be enrolled from the clinic at tu du hospital, ho chi minh city, vietnam. the standard regimen has been 100 mg twice daily for 5 days after the abortion. subjects will be randomized to the standard regimen or to take 200 mg doxycycline pre-operatively. subjects found to have a positive chlamydia eia test will receive a 7-day course of doxycycline regardless of study group. subjects will complete questionnaires of symptoms, including nausea and emesis in the recovery room after the procedure and at a single follow-up visit two weeks later. the primary outcome will be infection after abortion, defined below. analyses will be performed including and excluding chlamydia-positive subjects. secondary outcomes will be the proportion with nausea, emesis, and other side-effects.


Eligibility criteria:
inclusion criteria. 1. women seeking elective surgical abortion 2. gestational age 6 weeks 0 days to 12 weeks 6 days, confirmed by ultrasound. 3. willing and able to sign an informed consent. 4. willing to comply with the study protocol. 5. age at enrollment of 18 years or more. exclusion criteria 1. allergy to doxycycline or any tetracycline 2. evidence of current pelvic infection 3. breastfeeding 4. current or recent use (within the past 7 days) of any other antibiotic. 5. prior cardiac valve surgery or cardiac valve replacement. 6. active use of alcohol, heroin, or cocaine. post-enrollment exclusion criteria 1) abortion procedure not performed

Keywords: pelvic infection abortion doxycycline
the effect of emotional freedom technique on premenstrual syndrome

Conditions: Premenstrual Syndrome; Emotional Freedom Technique; Nursing Caries

Summary: introduction: premenstrual syndrome (pms) is a condition that occurs in the luteal phase of the menstrual cycle and affects women's lives physically, psychologically and behaviorally, starting approximately five days before menstruation and decreasing spontaneously a few days later. purpose: this research is planned to examine the effect of the emotional freedom technique on the experience of premenstrual syndrome and menstrual symptoms and the quality of life of nursing students with premenstrual syndrome. method: the research will be conducted with first, second, third and fourth year female students studying at dokuz eylül university faculty of nursing. diagnostic information form, premenstrual syndrome scale, menstruation symptom scale, sf-12 quality of life scale and subjective danger units will be collected via google form. sud scale will be applied. the research is designed with experimental and control groups, and it is found that a total of 70 female students are needed, 35 in the experimental group and 35 in the control group. pmss analysis will be performed and students who score over 132 points and meet the inclusion criteria will be numbered in the order of filling out the survey, and randomization will be done using the "random sequence generator" through www.random.org, which provides computer-assisted randomization, and experimental and control groups will be created. simple randomization will be applied to keep the control and experimental groups equal. to ensure blinding in the study, randomization will be carried out by someone other than the researchers. a total of 8 sessions of emotional freedom technique (eft) will be applied to the experimental group, once a week. no application other than the scales will planned for the control group.


Eligibility criteria:
inclusion criteria: * scoring over 132 on the premenstrual syndrome scale * over 18 years old * having had a regular menstrual cycle for the last three months (21-35) * owner of a smartphone and internet * agreeing to participate in the research exclusion criteria: * psychiatric treatment and antidepressant medication in the last three months who have started, * who are pregnant, * who have given birth, * who use oral contraceptives, * who have difficulty accessing the internet * who did not participate in the post-test will be excluded.

Keywords: premenstrual syndrome menstrual symptom life quality emotional freedom technique nursing care